TCL Archive Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint May 31, 2013
TCL Archive BCDDP Follow Up To Cost $1.6 Million annually For Five Years Okayed; Limited To 59,000 Women November 3, 1978
TCL Archive Oncogens Variations May Exaplin Susceptibility, Familial Cancer, USC Investigators Report September 23, 1988
TCL Archive Cancer Genome Atlas Reveals Similarities Between Certain Breast and Ovarian Cancers September 28, 2012
